News and Events

Clinical trial tests targeted radioactive agent as therapy for metastatic prostate cancer

Prostate-specific membrane antigen (PSMA) is present on the surface of all prostate cancer cells but is highly expressed on cells of castration-resistant prostate cancer (mCRPC). Frank Lin, M.D., Investigator in the the Molecular Imaging Program, is leading NCI’s effort to study the effect of targeted treatment with a radioactive agent to test dosing and overall effect for these patients.

A Conversation with Christina Annunziata, M.D., Ph.D.

Christina Annunziata, M.D., Ph.D., is an Investigator in the Women’s Malignancies Branch at the Center for Cancer Research. She has spent most of her career studying the molecular underpinnings of ovarian cancer with the goal of discovering novel treatments. In our Q&A, Dr. Annunziata discusses her personal and professional milestones as well as new directions for her research.

New chemical sequencing reaction helps unravel the role of an ancient RNA modification

CCR researchers and collaborators have developed a novel chemical reaction that enables the quantitative mapping of an ancient and enigmatic RNA modification that is found in nearly all organisms on earth, providing fundamental insights that are potentially important for tumor biology and cancer treatment.

Clinical trial studies CAR T-cell therapy for relapsed/refractory acute myeloid leukemia

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow, the soft inner part of long bones where new blood cells are made. With AML, bone marrow cells don't grow the way they're supposed to. Instead, immature bone marrow cells grow uncontrollably and build up in the body. This study is testing the effect of chimeric antigen receptor T cells (CAR T cells) for children and young adults.

New clinical trial evaluates chemotherapy delivery for stomach cancer

A clinical trial testing chemotherapy delivery for stomach cancer that has spread to the lining of abdominal cavity is underway at the NIH Clinical Center. Investigators are evaluating how this delivery may improve outcomes for patients with this rare condition.

CCR presentations at AACR 2020 - Session II

The American Association for Cancer Research (AACR) Annual Meeting covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. The 2020 AACR Virtual Annual Meetings I and II will take place April 27-28 and June 22-24, respectively. View the list of CCR presenters for the June meeting.

CCR scientists develop new blood test that may improve liver cancer screening

Scientists led by Xin Wei Wang, Ph.D., Deputy Chief of the Laboratory of Human Carcinogenesis, have developed a new test that can identify people who are likely to develop hepatocellular carcinoma (HCC), the most common form of liver cancer. The approach uses a simple blood test to check for the patient’s previous exposure to certain viruses. “Together with existing screening tests, the new test could play an important role in screening people who are at risk for developing HCC. It could help doctors find and treat HCC early. The method is relatively simple and inexpensive, and it only requires a small amount of blood,” he says.

In Memoriam: Isaiah Fidler, D.V.M, Ph.D.

The Center for Cancer Research mourns the recent death of past colleague and friend Isaiah Fidler, D.V.M., Ph.D. He joined the National Cancer Institute in 1975 and led the metastasis program at the Frederick Cancer Research Facility. His eight years at NCI produced some of his early innovative work in unraveling the riddles of how cancer spreads.

A Conversation with Bríd Ryan, Ph.D., M.P.H.

Bríd Ryan, Ph.D., M.P.H., is an NIH Stadtman Investigator in the Laboratory of Human Carcinogenesis at the Center for Cancer Research. Her research focuses on health disparities related to lung cancer across different populations. She discusses her latest research findings and future directions of her work as well as the importance of the supportive CCR environment in this Q&A.

Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma

In a new study, an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. The study was led by researchers in the Center for Cancer Research, and the DA-EPOCH-R regimen was originally developed by researchers led by Wyndham Wilson, M.D., Ph.D., Senior Investigator in the Lymphoid Malignancies Branch.

Breadcrumb